Drug Trial Radar · NCT02060903
A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Last checked: Nov 20, 2026Latest source record: Sep 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
379
Actual
Start
Feb 2014
Primary completion
Jul 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Dr. Reddy's Laboratories Limited, IndiaIndustry
- Sponsor type
- Industry
- Collaborators
- Accelovance; Syneos Health
- First posted
- Feb 12, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the scalp and hair for 10 minutes at home.
Conditions
- Head Lice Infestation
Interventions
Abametapir Lotion 0.74% w/wDrug
Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
Vehicle LotionDrug
Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.Time frame: 14 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Universal Biopharma Reserach INC
Dinuba, California
Axis Clinical Trials
Los Angeles, California
LSRN Reserach
West Palm Beach, Florida
Impact Clinical Trials
Las Vegas, Nevada
Haber Dermatology
Beachwood, Ohio
McKenzie Medical Center
McKenzie, Tennessee
Radiant reserach Inc.
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.